Status:

COMPLETED

Safety and Performance Aspects of CRT-DX System in Patients With Sinus Rhythm

Lead Sponsor:

Biotronik SE & Co. KG

Conditions:

Heart Failure

Cardiac Resynchronization Therapy

Eligibility:

All Genders

18+ years

Brief Summary

The conventional CRT-D system consists of 3 leads in patients with Heart Failure (HF). A part of HF patients have non-impaired sinus node function and will not be stimulated in the right atrium. The i...

Eligibility Criteria

Inclusion

  • Patient is able to understand the nature of study and has provided written informed consent.
  • Patient is willing and able to perform all follow up visits at the study site.
  • Patient is willing and able to use the CardioMessenger® and accepts the BIOTRONIK Home Monitoring® concept.
  • CRT-D is indicated according to the current ESC guidelines.
  • De novo implantation with no pre-existing defibrillator or pacemaker system
  • Patient is in sinus rhythm without history of persistent or permanent atrial fibrillation.
  • Patient has no atrioventricular (AV) block II or III.
  • Patient has no evidence of impaired sinus node function.
  • Patient has no need for atrial stimulation, has a resting heart rate (HR) \> 40 b.p.m and achieves a peak HR ≥100 b.p.m even under intended dosage of HR lowering medication verified by an appropriate method as clinical routine examination within 3 months prior to enrollment
  • NYHA class II or III
  • Patient receives guideline-based optimized medical therapy for HF including heart-rate lowering medication at the time of enrollment

Exclusion

  • Patient is pregnant or breast feeding.
  • Patient is less than 18 years old.
  • Patient is participating in an interventional clinical investigation.
  • Life-expectancy is less than 1 year.
  • Patient has tachycardia-bradycardia syndrome
  • Any standard contraindication for CRT-D
  • Frequent premature ventricular contractions (PVC rate \> 5 %/h) examined within 3 months prior to enrollment by appropriate routine method (e.g. 24 h holter electrocardiogram)

Key Trial Info

Start Date :

April 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

June 8 2023

Estimated Enrollment :

113 Patients enrolled

Trial Details

Trial ID

NCT03839121

Start Date

April 1 2019

End Date

June 8 2023

Last Update

April 9 2025

Active Locations (21)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 6 (21 locations)

1

Kepler University Clinic

Linz, Austria

2

Fakultni Nemocnice Hradec Králové

Králová, Czechia

3

Fakultni Nemocnice Olomouc

Olomouc, Czechia

4

RHÖN-KLINIKUM Campus Bad Neustadt

Bad Neustadt an der Saale, Germany